{"ticker": {"uuid": "3752e5e7-76ec-446c-b51b-d4b3bc0dc8a4", "symbol": "CYTK", "name": "Cytokinetics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy", "summary": "Cytokinetics (CYTK) has received an upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This rating change signifies a positive outlook for the company's earnings and could lead to increased buying pressure and stock price appreciation. The Zacks Ra", "url": "https://sg.finance.yahoo.com/news/know-cytokinetics-cytk-rating-upgrade-160005677.html", "source_name": "Market source", "published_at": "2026-07-15T15:41:12", "published_display": "15 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNdDBtcTdRcE9weXlERzlrUDdQTFlBWURsNTJWWTNZZXpyRWFxUTlnckl5X1dVenRZYnRMWlV5OEZKdXRkcThjd2R3VE9mOEl4N2JqbEpkbFY1Tk5UdTllZlBraE1VdWRwM2U5bGFmYWlJS1FNVnp6N2JYZG0yRk96NXlrM0Q4N2I0UV9reVFBWlBydw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:55:02+00:00", "published_display": "15 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative", "summary": "Cytokinetics (CYTK) is considered 22% undervalued based on a narrative fair value of $105.60, despite recent insider share sales. The company exhibits strong momentum with a significant share price return over the past year, driven by an expanding addressable market due to aging ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-could-be-22-undervalued-on-its-growth-narr/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:41:10", "published_display": "15 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing", "summary": "An insider at Cytokinetics sold shares worth $615,150, as reported in a recent SEC filing. This transaction involved a significant amount of stock, indicating a notable insider sale. The article details the financial specifics of this sale for the company insider.", "url": "https://www.moomoo.com/news/post/72956497/cytokinetics-insider-sold-shares-worth-615150-according-to-a-recent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T03:41:12", "published_display": "15 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWGYtdG1IdnB4YmxUSEJFVUg1anVNWmtDazM0dmdKRkdJaGJXcEVFR0dwRFhKUF9vSFZmblZ1c1JYQmVrMkJHMXl0U2NqWEV6Rm9SdWMzYS1CNmpHZjdINlVtRG0xVF9HRFVZOU9IeG9va1p5eEdVcl9YOVdxWks0NHU5bGhZM3ZpcndDSTZhRG91bFVHUnhkWG11cl83ZVNXTEtSa3NGSWdYOVlVUWJXZnFBRnBpS3BkWkE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-14T22:20:00+00:00", "published_display": "14 Jul 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics president & CEO Robert Blum sells $615,149 of stock", "summary": "Robert I. Blum, President & CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of company common stock for a total of $615,149 on July 13, 2026, at a price of $82.02 per share. This sale followed the exercise of stock options for 7,490 shares at $10.60 per share, significa", "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-president--ceo-robert-blum-sells-615149-of-stock-93CH-4791538", "source_name": "Investing.com", "published_at": "2026-07-14T20:41:11", "published_display": "14 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cytokinetics Inc For: 14 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Cytokinetics Inc on July 14th. The content is very brief, mainly serving as a headline for a regulatory filing and providing links to financial market data and other news from Investing.com. It indicates that th", "url": "https://ca.investing.com/news/stock-market-news/form-4-cytokinetics-inc-for-14-july-93CH-4733774", "source_name": "Investing.com Canada", "published_at": "2026-07-14T20:21:21", "published_display": "14 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics president & CEO Robert Blum sells $615,149 of stock By Investing.com", "summary": "Cytokinetics President & CEO Robert Blum sold 7,500 shares of company stock worth $615,149 on July 13, 2026, after acquiring shares through stock option exercises. These transactions occurred amidst positive developments for Cytokinetics, including the commercial launch of its he", "url": "https://ca.investing.com/news/stock-market-news/cytokinetics-president--ceo-robert-blum-sells-615149-of-stock-93CH-4733772", "source_name": "Investing.com Canada", "published_at": "2026-07-14T19:21:22", "published_display": "14 Jul 2026 19:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Inc (CYTK) CEO exercises options and sells 7,500 shares", "summary": "Cytokinetics Inc's President & CEO, Robert I. Blum, exercised non-qualified stock options for 7,490 shares at $10.60 per share and subsequently sold 7,500 shares at $82.02 per share in open-market transactions. Following these transactions, Blum directly holds 377,820 shares, wit", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-50e6acc06785.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:21:21", "published_display": "14 Jul 2026 19:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 27% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQQkVIRHJURWlpTDhNbnJHVWRyTXVxdDRaQjZMSHBLdE9WZ01TZG41dUpRbjJTNU1RbzY2SGRxYnpjWU1NV1E2UnhETl9iNWEwSy1IalEyeFNqbVZkTTIxRk1sSm9EM180emJsTGRudTFycWFVc2lGUFhBc2FQMFhhR0lIZmZTVFNLSGY1YXRhNDNPa3ptdkI0MllaVmI0LTkySXRDd0RFc2hidzdOLUdrb3ZyOEJ0LV9NQjhSeC1WYm03TnlwTFBiNG8zbElIaGtaU3hCREh2dGZrZw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:27+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Myqorzo\u2019s US and German Launches Will Impact Cytokinetics (CYTK) Investors", "summary": "Cytokinetics has transitioned from a development-stage biotech to a commercial company with the launches of Myqorzo in the US and Germany. This shift puts focus on regulatory execution, real-world physician adoption, and payer access as key drivers for the company's future succes", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/how-myqorzos-us-and-german-launches-will-impact-cytokinetics", "source_name": "Simply Wall Street", "published_at": "2026-07-12T05:09:24", "published_display": "12 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQMUEwM1g5aWl1TWE3aEc5d2dzc3MtcGpUSHhaNkZEZU16bmlwaFNxZzFuNDlJYWNDNE1SbWtwMVNhVlJoU0NpS0Q5VnZMaWRJTWNXT0pxa09kS2w5NElNNnIyRG9WeExhNW9uT1ZldHE4MWR6amduQTNqMEZjUGRaYkZkTkVFT3JvdmRrSlYtajBNVzUzS1dqaGw5WDVKSGxHSXlVRnZ3?oc=5", "source_name": "Market source", "published_at": "2026-07-11T06:13:24+00:00", "published_display": "11 Jul 2026 06:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Myqorzo\u2019s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMnB3RVc0enEwU1JIUVZ2RTh1b3JxUzBXd2ZkTnZiQzl6bHlROEhWWWRwX2FrdFBYbWdqQjNGM2hhcFRzb1ZsMzFLR2FEdW9CM0RmNnd6ckViSHhrTDVNdm5oVVZKSVZodlRFLVhmRFktaWNTM1VQNGdVNG50cTNHZVF2OXc2SmhWc2ZzbVRWOElVbHVHUDQ2RmNxVmF2dGVOVkp2aVdTVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-11T01:12:00+00:00", "published_display": "11 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cytokinetics, Incorporated \u2013 NASDAQ:CYTK", "summary": "This article provides the \"Price to sales forward\" metric for Cytokinetics, Incorporated (NASDAQ: CYTK). It lists the period, value, and change percentage for this financial indicator, and appears to be a snippet from a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CYTK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T22:09:49", "published_display": "10 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/myqorzo-drive-cytokinetics-higher-despite-181000834.html", "source_name": "Zacks", "published_at": "2026-07-10T18:10:00+00:00", "published_display": "10 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics, Incorporated Stock 12\u2011Month Price Target Raised to $108.47, Implies 26% Upside", "summary": "The average 12-month price target for Cytokinetics, Incorporated stock has increased from $107.8 to $108.47, with analysts' forecasts ranging from $83 to $146 per share. This updated target implies an approximately 26% potential upside based on the July 9 closing price. The conse", "url": "https://www.tradingview.com/news/tradingview:bb4c4eae32122:0-cytokinetics-incorporated-stock-12-month-price-target-raised-to-108-47-implies-26-upside/", "source_name": "TradingView", "published_at": "2026-07-10T07:09:31", "published_display": "10 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Could Be 19% Undervalued After Phase 3 ESC Abstract News", "summary": "Cytokinetics (CYTK) is under renewed scrutiny after news of Phase 3 ACACIA-HCM results for aficamten being accepted for presentation at the European Society of Cardiology Congress. Despite recent share price momentum, analysts suggest the stock is 19% undervalued with a fair valu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-could-be-19-undervalued-after-phase-3-esc", "source_name": "Simply Wall Street", "published_at": "2026-07-09T02:09:49", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A", "summary": "FMR LLC has filed an amended passive investment disclosure (Schedule 13G/A) for Cytokinetics (NASDAQ: CYTK), reporting a beneficial ownership of 5,248,579.71 shares, which represents a 3.9% stake in the company as of June 30, 2026. The filing indicates that FMR LLC holds sole dis", "url": "https://www.stocktitan.net/sec-filings/CYTK/schedule-13g-a-cytokinetics-inc-amended-passive-investment-disclosure-5a4bd69fae7a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:09:45", "published_display": "08 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026", "summary": "Cytokinetics announced that three Late-Breaking Science abstracts, including primary results from the ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), have been accepted for presentation at the European Society of Cardiology (E", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323061/35409/en/cytokinetics-announces-three-late-breaking-science-abstracts-at-the-european-society-of-cardiology-esc-congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T03:09:24", "published_display": "08 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK Maintained by RBC Capital -- Price Target Lowered to $117", "summary": "RBC Capital has maintained an \"Outperform\" rating on Cytokinetics (CYTK) but lowered the price target from $119 to $117. Despite this adjustment, GuruFocus indicates that CYTK is significantly undervalued by 65.7%, with a current price of $85.57 against a GF Value of $249.16. The", "url": "https://www.gurufocus.com/news/8947929/cytk-maintained-by-rbc-capital-price-target-lowered-to-117", "source_name": "GuruFocus", "published_at": "2026-07-08T01:40:51", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale", "summary": "Cytokinetics (NASDAQ: CYTK) has filed a Form 144 notice indicating a proposed sale of 24,500 shares of Common Stock through the exercise of stock options on July 7, 2026, with the sale method listed as cash. The filing also disclosed five previous 10b5-1 sales, each for 3,500 sha", "url": "https://www.stocktitan.net/sec-filings/CYTK/144-cytokinetics-inc-sec-filing-5b903de62e87.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:51", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market", "summary": "CYTOKINETICS' EVP of Research & Development, Fady Ibraham Malik, reported an exercise-and-sale transaction, selling 3,500 shares of common stock at $86.62 per share after exercising options to acquire the same number of shares at $7.80 per share. Following these transactions, Mal", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-722b24b08af2.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:51", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Announces Three Late-Breaking Science", "summary": "Cytokinetics (Nasdaq: CYTK) will present three Late-Breaking Science abstracts at the European Society of Cardiology (ESC) Congress in August 2026, including primary results from the pivotal ACACIA-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM). The ", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323061/0/en/Cytokinetics-Announces-Three-Late-Breaking-Science-Abstracts-at-the-European-Society-of-Cardiology-ESC-Congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T13:41:28", "published_display": "07 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating", "summary": "RBC Capital has updated its price target for Cytokinetics, Inc. (CYTK) to $117, down from $119, while reaffirming its Outperform rating on the stock. The adjustment reflects an updated valuation by RBC Capital analysts. Cytokinetics is a biopharmaceutical company focused on devel", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-cytokinetics-price-target-to-117-from-119-maintains-outperform-rating-ce7f5ed8d98efe20", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T12:18:30", "published_display": "07 Jul 2026 12:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics lands three ESC 2026 presentations on heart drug data", "summary": "Cytokinetics (Nasdaq: CYTK) announced that three Late-Breaking Science abstracts have been accepted for presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich. These presentations will include primary Phase 3 ACACIA-HCM results for aficamten in non-obstr", "url": "https://www.stocktitan.net/news/CYTK/cytokinetics-announces-three-late-breaking-science-abstracts-at-the-ya17z2nhdy4a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:15:30", "published_display": "07 Jul 2026 11:15", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK - Cytokinetics Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings and comprehensive financial data for Cytokinetics Inc. (CYTK). It details metrics such as market capitalization, sales, earnings per share (EPS), insider and institutional ownership, profitability ratios, and stock performance over variou", "url": "https://finviz.com/stock?t=CYTK&ty=lf&ta=1&p=w&page=21", "source_name": "Finviz", "published_at": "2026-07-06T05:11:20", "published_display": "06 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com", "summary": "Cytokinetics CEO Robert Blum sold 7,500 shares of company stock worth approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Mr. Blum directly holds 377,830 shares, while the company's stock trades near its 52-week high, having retur", "url": "https://ng.investing.com/news/stock-market-news/cytokinetics-ceo-robert-blum-sells-636900-in-stock-93CH-2585261", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T00:40:39", "published_display": "03 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics CEO Robert Blum sells $636,900 in stock", "summary": "Cytokinetics CEO Robert Blum sold 7,500 shares of the company's common stock for approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following the sale, he directly holds 377,830 shares. The transaction occurs as Cytokinetics shares trade near their 52-week ", "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-ceo-robert-blum-sells-636900-in-stock-93CH-4774389", "source_name": "Investing.com", "published_at": "2026-07-02T21:40:18", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79", "summary": "CYTOKINETICS (NASDAQ: CYTK) EVP and CFO Sung Lee reported exercising 1,112 non-qualified stock options at $48.51 per share and subsequently selling the same number of common shares at $87.79 per share in an open-market transaction. Following these transactions, Lee directly holds", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-3527afafd186.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cytokinetics Inc For: 2 July By Investing.com", "summary": "Investing.com reports on a Form 4 filing for Cytokinetics Inc. on July 2nd. The article reiterates this information and provides general market data, including various stock market indices, commodity prices, bond yields, and trending stocks. It also features popular financial new", "url": "https://ca.investing.com/news/stock-market-news/form-4-cytokinetics-inc-for-2-july-93CH-4719193", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80", "summary": "Andrew Callos, EVP of Cytokinetics (NASDAQ: CYTK), exercised options to acquire 15,000 shares of common stock at $23.26 per share and subsequently sold all 15,000 shares in an open-market transaction at an average price of $85.80 per share on July 1, 2026. Following these transac", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-e4ea3d55d050.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale", "summary": "Cytokinetics President & CEO Robert I. Blum sold 7,500 shares of CYTK common stock at $84.92 per share in an open-market transaction on July 1, 2026. Following the sale, Blum directly holds 377,830 shares, with an additional 2,083 shares each held indirectly by two irrevocable tr", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-60c4f7ceaa9c.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK)", "summary": "Robert Blum, an insider at Cytokinetics Inc. (CYTK), has filed a Form 144 to report planned sales of company stock, including 44,990 shares from stock option exercise and 7,510 shares from Restricted Stock Units. The filing also details several completed 10b5-1 sales of 7,500 sha", "url": "https://www.stocktitan.net/sec-filings/CYTK/144-cytokinetics-inc-sec-filing-f9b5b5aa47e6.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:28", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Is Up 6.5% After Myqorzo\u2019s Early Commercial Uptake Signals Growing Clinical Interest \u2013 Has The Bull Case Changed?", "summary": "Cytokinetics is seeing a 6.5% stock increase driven by the early commercial success of its heart drug, Myqorzo, which has received regulatory approvals in the US, Europe, and China. The early adoption by physicians and patients is validating the drug's potential, shifting the com", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-up-65-after-myqorzos-early-commercial-u", "source_name": "Simply Wall Street", "published_at": "2026-06-30T22:23:16", "published_display": "30 Jun 2026 22:23", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Inc stock hits 52-week high at $88.00", "summary": "Cytokinetics Inc (CYTK) stock reached a new 52-week high of $88.00, marking a significant 159.39% increase over the past year due to substantial revenue growth and positive analyst sentiment. The company's heart drug, Myqorzo, has seen a successful commercial launch in Germany an", "url": "https://www.investing.com/news/company-news/cytokinetics-inc-stock-hits-52week-high-at-8800-93CH-4768090", "source_name": "Investing.com", "published_at": "2026-06-30T13:40:16", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Prepares for Commercial Rollout Following Regulatory Approvals Across Major Markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxPNWMzTVNSb3UzVTBJLW5XTFF2T2pTMUdmcWNsM25LWXlsN2VkR3d6UU5qR2IzX0ZTTlBITTU1LUJWdHRKOGsyNFBOTjFEdnNGVklPVzZ2cU1qVUppd0hlc3drVzZjZDJNbWRibEtNLUM2N1J4U1BFV0JhQWxuNDlJSkFaRURSVXNOdDhPT0xNUWFOWkgzcjE1dWxPU09ncWI1RHJfRjBVb3NDQnZQazdzRnduVG5GVDNiYjdEM3FpUVBkb0pFM3V0bU1GZU5zMzZrQVdBWDNDeEZNVGFUUzBYczRPcVhTTkdKLTBFN2tkRm9NbEF5WDhpY2xCS2dVMzdJV0dqaFFQSEVVeDVadUd5NTh5LU9WSDg?oc=5", "source_name": "TIKR.com", "published_at": "2026-06-30T12:26:31+00:00", "published_display": "30 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWE82SE0yeTZlbFdFSDhnN2ttZXVEdlN3N3VmSUZuRE5YN3BjNFZiNkxmLTZXY0hqc1FlcDFXQXhfOTVndmh3UTZvWkJPZnZ4NWUwSkJ5TS05UUR0QmVuTWJKTlJQa0ZvcEZvTXZUam8wbGRBVmJBMVhTU1RzSTRMQVZvZHhTU3RBOVlaYWJaUnJhNTRuWGpBa1J0b2JmM2xaTF9ZTHRtOFJGdw?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Stock Surges 19%, With A 8-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNGE3S3BGQ2Zmc2Z5TnVjX3pyWWROWTFxWVlYS0tQUFhvZXBSeUwwTTdQWXhGUzJEZ1IwY1JxUWY0SVJ5SlV1aUYzb2RVQXctRG5wUDlyY3duTWt5RTFtQ2ZPM2MxV3RzZHBfaENRdHN5N0FNRmFIQ2ZxZ1hoaHYwaTJnSFQyOEh6YU1Hdm8zbVRJeDVGeHktLTNOODI4eVg3ajJHc0VMUUs5anpfS0lkdGZNTjFJWGhBUnFhUFNCVzVRWWM?oc=5", "source_name": "Trefis", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Stock 6-Day Winning Spree: Stock Climbs 17%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQaVZ1djhmOVhCOF81NnMxLTFVNTdaSVcxWDBiQmNkM3dBY2UyTmswdm1lMlo3X2kzUmdCMjZTN1NvY2VYSEhSNVJLX3R3Skg2TjFkc051VXVROFU5RmNnX3piVnNBTmlld1NwSExUWWxqRGU4eXRGRmhWdHhsdnBlbUJuLWRtSjYwVVd1Y2doQ2RrLWFPQTFUSjdoMDBYVEVtSjNiNDdWdlFldlEyUjYxVU5lU004dw?oc=5", "source_name": "Trefis", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOc05hRUszeF9MX1NiZDQxcTQ4dnRXeDhtOXZCQnVONDNlUDFBazg3aWZnOXVRYmp3TUVBR1o4dFlyUjhZb1V2ajZwVEtoR0NibDNPMDhuemRrbE1iMVFOVy1QMGFtRjE2XzNBQUxLV2Fna2U1Q0dkU3pWdVhHQVVWYkwtSURLNUZ4TEw0eDFVN3BPTzQ?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics, Inc. (CYTK) Stock Analysis: Exploring a 36.40% Potential Upside in the Biotechnology Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNaU80UGpqb0p0RVIydjN3TGlBNDBrMHhBQ0ZycmdaN0dMcWVRSzVRODhsT3hOemVXQkZaZ2RVTUpRNk5TZS10bFBtcmlBdDctUzJTZGNEallHd01zRzBMRENjODZyZVBVT2Y5NW9rMkVURU5XYzF1UTZPLXhtX3pRM3puSmF4UDVjVUQ0cDMyc2I4TUZGbkstTWw4UEFMaWlHbndQd3BBblJUQ0gwMlpDanZXR1ZHOVBMWlRrcThQZzBmODktcVlaRmMzbEFGX2RTdnFaR283WDdIRDFleEFOc0Fvd0c?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Cytokinetics (CYTK) Valuation After A Strong Multi\u2011Year Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeFQ2SHdnb0VMSW1tSWNQWUdOTzdtakxsYkpQTVotUTZQaVZpUmtTRmNaVnJmWHNKRUZ0LS1TLU02UWhGakkwTzFhb1hWZHI3R0llM1loLVExbnMyamZjemY1MlM0YndGQkhlcjZVNlljRmxwdUd4M0VrSGI0U0Zhcmd0akp0b3pMWXdVRnNST2ZJVDJLaEFDMG5JRldiSlJQRDlwWm1iNA?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: Analysts Are Much More Bullish On Cytokinetics, Incorporated (NASDAQ:CYTK) Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$805M raised as Cytokinetics sells 11.3M shares at $71 each", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQangwS3ZVZjdTSkR5Ylk5X1ZzNmtsc0JuYW5tX19adVhwTk1TOWtFQl9zM3FmTzctUTNDd0FaaUpqVWZGR2ZaZHVTdlVEZmVRTGxlTWJRczhjMGVSWDBySTRvWXh5M3gzOHF2THB1c3NGYkRaTG0zYjNSQWRCMm1CRkkwTW1kOTRzcTBnZnlROHFrb1YzNXhuOEdNRFVhZnNRYmRINDVyeEhEdWl3MGhNOUQ3dVJpZjRUWGxvQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC increases stake in Cytokinetics (NASDAQ: CYTK) to 9.0%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOV0lLanEwTmtPSmNySE9yZllWV3hHUkdNMTBXYTRxOWd5VUkzYTliQUNValJGb2lVMVE1ZTR4X3RMc2ZXY0JrS3EtakxRZHVtRU1GZDlVWEZCV180bXFtOVljTHQwUEN5TkdkenFhX2djbEFvYVJoMy1aaGVJeWJSOWJmbVJDbWxCdUpWZ2NmZ253cTFIaHNyQjk1MWZ1NXJ2OENNMnJSSGRrV3FVbXdvSzhVUEtJcGdYRmJqRkdTaUxPc3dua2hqZnVsNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNb1V4MGVfb0pYTjdFLWM2UzJoSVV3UzhlNmgyY1J3VGk5ZHdodE1ydDkyX3djVmYtd3ZVTkhxVVZleTdmME9PRFdSODRNT2pFVm0tU010T0xvN1RWS1dKN0k2UDdEMjNKRTBvOGxjcVdsVFF2WmVUYWxYcWtmOUpqRDdDaklXVWtVUjE3TWFVWU1pN0dSQWszR3E0bWlxRU94clVkMnNuX3VNSk5xeFRxakU1aFBTRVhaQWhMUkNSTEJLZw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000%", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQelU4T0djbjVOTW5KRHlRSEIzWFgxOUxXbTZZMHo4NWpjbGd6NzZGazlzRkMyRkRNcFhIYXNxeFE0c0VlQUE2SWlkcXYwNG5paWw5cjFvVEZsQVpHQXJKUU56SWY3UEtxOGtZU2ptV0NzaG4yeUZ4U3U1NTZFTlc3VTUtTTJuYjlpdDBOZ1VTeHl5YWZTNnpTVG5NQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOa1ZjbzhlVFJxMk9Lc1RMc2dBeW5qUEx6cDZQVkZuVHpKZ3RkVWcwYlh4bF9xZDg2VE5IRE9uZV9QeXFjYXg0TmhZUmtaYkppM0dqOVFWM0hZdjE0ZGR5dXFsREVaWkFkVjlvY1ZHS1UzM2dwRnUxRlRWa25fSGRjaHRGWXk3cklOY0xKU21KUmJ2dkg3RHRONXJsbkVLMWc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Cytokinetics (CYTK) After Its 62% One-Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy", "summary": "Cytokinetics (CYTK) has received an upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This rating change signifies a positive outlook for the company's earnings and could lead to increased buying pressure and stock price appreciation. The Zacks Ra", "url": "https://sg.finance.yahoo.com/news/know-cytokinetics-cytk-rating-upgrade-160005677.html", "source_name": "Market source", "published_at": "2026-07-15T15:41:12", "published_display": "15 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNdDBtcTdRcE9weXlERzlrUDdQTFlBWURsNTJWWTNZZXpyRWFxUTlnckl5X1dVenRZYnRMWlV5OEZKdXRkcThjd2R3VE9mOEl4N2JqbEpkbFY1Tk5UdTllZlBraE1VdWRwM2U5bGFmYWlJS1FNVnp6N2JYZG0yRk96NXlrM0Q4N2I0UV9reVFBWlBydw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:55:02+00:00", "published_display": "15 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative", "summary": "Cytokinetics (CYTK) is considered 22% undervalued based on a narrative fair value of $105.60, despite recent insider share sales. The company exhibits strong momentum with a significant share price return over the past year, driven by an expanding addressable market due to aging ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-could-be-22-undervalued-on-its-growth-narr/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:41:10", "published_display": "15 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing", "summary": "An insider at Cytokinetics sold shares worth $615,150, as reported in a recent SEC filing. This transaction involved a significant amount of stock, indicating a notable insider sale. The article details the financial specifics of this sale for the company insider.", "url": "https://www.moomoo.com/news/post/72956497/cytokinetics-insider-sold-shares-worth-615150-according-to-a-recent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T03:41:12", "published_display": "15 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWGYtdG1IdnB4YmxUSEJFVUg1anVNWmtDazM0dmdKRkdJaGJXcEVFR0dwRFhKUF9vSFZmblZ1c1JYQmVrMkJHMXl0U2NqWEV6Rm9SdWMzYS1CNmpHZjdINlVtRG0xVF9HRFVZOU9IeG9va1p5eEdVcl9YOVdxWks0NHU5bGhZM3ZpcndDSTZhRG91bFVHUnhkWG11cl83ZVNXTEtSa3NGSWdYOVlVUWJXZnFBRnBpS3BkWkE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-14T22:20:00+00:00", "published_display": "14 Jul 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics president & CEO Robert Blum sells $615,149 of stock", "summary": "Robert I. Blum, President & CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of company common stock for a total of $615,149 on July 13, 2026, at a price of $82.02 per share. This sale followed the exercise of stock options for 7,490 shares at $10.60 per share, significa", "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-president--ceo-robert-blum-sells-615149-of-stock-93CH-4791538", "source_name": "Investing.com", "published_at": "2026-07-14T20:41:11", "published_display": "14 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cytokinetics Inc For: 14 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Cytokinetics Inc on July 14th. The content is very brief, mainly serving as a headline for a regulatory filing and providing links to financial market data and other news from Investing.com. It indicates that th", "url": "https://ca.investing.com/news/stock-market-news/form-4-cytokinetics-inc-for-14-july-93CH-4733774", "source_name": "Investing.com Canada", "published_at": "2026-07-14T20:21:21", "published_display": "14 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics president & CEO Robert Blum sells $615,149 of stock By Investing.com", "summary": "Cytokinetics President & CEO Robert Blum sold 7,500 shares of company stock worth $615,149 on July 13, 2026, after acquiring shares through stock option exercises. These transactions occurred amidst positive developments for Cytokinetics, including the commercial launch of its he", "url": "https://ca.investing.com/news/stock-market-news/cytokinetics-president--ceo-robert-blum-sells-615149-of-stock-93CH-4733772", "source_name": "Investing.com Canada", "published_at": "2026-07-14T19:21:22", "published_display": "14 Jul 2026 19:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Inc (CYTK) CEO exercises options and sells 7,500 shares", "summary": "Cytokinetics Inc's President & CEO, Robert I. Blum, exercised non-qualified stock options for 7,490 shares at $10.60 per share and subsequently sold 7,500 shares at $82.02 per share in open-market transactions. Following these transactions, Blum directly holds 377,820 shares, wit", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-50e6acc06785.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:21:21", "published_display": "14 Jul 2026 19:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 27% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQQkVIRHJURWlpTDhNbnJHVWRyTXVxdDRaQjZMSHBLdE9WZ01TZG41dUpRbjJTNU1RbzY2SGRxYnpjWU1NV1E2UnhETl9iNWEwSy1IalEyeFNqbVZkTTIxRk1sSm9EM180emJsTGRudTFycWFVc2lGUFhBc2FQMFhhR0lIZmZTVFNLSGY1YXRhNDNPa3ptdkI0MllaVmI0LTkySXRDd0RFc2hidzdOLUdrb3ZyOEJ0LV9NQjhSeC1WYm03TnlwTFBiNG8zbElIaGtaU3hCREh2dGZrZw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:27+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Myqorzo\u2019s US and German Launches Will Impact Cytokinetics (CYTK) Investors", "summary": "Cytokinetics has transitioned from a development-stage biotech to a commercial company with the launches of Myqorzo in the US and Germany. This shift puts focus on regulatory execution, real-world physician adoption, and payer access as key drivers for the company's future succes", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/how-myqorzos-us-and-german-launches-will-impact-cytokinetics", "source_name": "Simply Wall Street", "published_at": "2026-07-12T05:09:24", "published_display": "12 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQMUEwM1g5aWl1TWE3aEc5d2dzc3MtcGpUSHhaNkZEZU16bmlwaFNxZzFuNDlJYWNDNE1SbWtwMVNhVlJoU0NpS0Q5VnZMaWRJTWNXT0pxa09kS2w5NElNNnIyRG9WeExhNW9uT1ZldHE4MWR6amduQTNqMEZjUGRaYkZkTkVFT3JvdmRrSlYtajBNVzUzS1dqaGw5WDVKSGxHSXlVRnZ3?oc=5", "source_name": "Market source", "published_at": "2026-07-11T06:13:24+00:00", "published_display": "11 Jul 2026 06:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Myqorzo\u2019s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMnB3RVc0enEwU1JIUVZ2RTh1b3JxUzBXd2ZkTnZiQzl6bHlROEhWWWRwX2FrdFBYbWdqQjNGM2hhcFRzb1ZsMzFLR2FEdW9CM0RmNnd6ckViSHhrTDVNdm5oVVZKSVZodlRFLVhmRFktaWNTM1VQNGdVNG50cTNHZVF2OXc2SmhWc2ZzbVRWOElVbHVHUDQ2RmNxVmF2dGVOVkp2aVdTVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-11T01:12:00+00:00", "published_display": "11 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cytokinetics, Incorporated \u2013 NASDAQ:CYTK", "summary": "This article provides the \"Price to sales forward\" metric for Cytokinetics, Incorporated (NASDAQ: CYTK). It lists the period, value, and change percentage for this financial indicator, and appears to be a snippet from a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CYTK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T22:09:49", "published_display": "10 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/myqorzo-drive-cytokinetics-higher-despite-181000834.html", "source_name": "Zacks", "published_at": "2026-07-10T18:10:00+00:00", "published_display": "10 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics, Incorporated Stock 12\u2011Month Price Target Raised to $108.47, Implies 26% Upside", "summary": "The average 12-month price target for Cytokinetics, Incorporated stock has increased from $107.8 to $108.47, with analysts' forecasts ranging from $83 to $146 per share. This updated target implies an approximately 26% potential upside based on the July 9 closing price. The conse", "url": "https://www.tradingview.com/news/tradingview:bb4c4eae32122:0-cytokinetics-incorporated-stock-12-month-price-target-raised-to-108-47-implies-26-upside/", "source_name": "TradingView", "published_at": "2026-07-10T07:09:31", "published_display": "10 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Could Be 19% Undervalued After Phase 3 ESC Abstract News", "summary": "Cytokinetics (CYTK) is under renewed scrutiny after news of Phase 3 ACACIA-HCM results for aficamten being accepted for presentation at the European Society of Cardiology Congress. Despite recent share price momentum, analysts suggest the stock is 19% undervalued with a fair valu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-could-be-19-undervalued-after-phase-3-esc", "source_name": "Simply Wall Street", "published_at": "2026-07-09T02:09:49", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A", "summary": "FMR LLC has filed an amended passive investment disclosure (Schedule 13G/A) for Cytokinetics (NASDAQ: CYTK), reporting a beneficial ownership of 5,248,579.71 shares, which represents a 3.9% stake in the company as of June 30, 2026. The filing indicates that FMR LLC holds sole dis", "url": "https://www.stocktitan.net/sec-filings/CYTK/schedule-13g-a-cytokinetics-inc-amended-passive-investment-disclosure-5a4bd69fae7a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:09:45", "published_display": "08 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026", "summary": "Cytokinetics announced that three Late-Breaking Science abstracts, including primary results from the ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), have been accepted for presentation at the European Society of Cardiology (E", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323061/35409/en/cytokinetics-announces-three-late-breaking-science-abstracts-at-the-european-society-of-cardiology-esc-congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T03:09:24", "published_display": "08 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK Maintained by RBC Capital -- Price Target Lowered to $117", "summary": "RBC Capital has maintained an \"Outperform\" rating on Cytokinetics (CYTK) but lowered the price target from $119 to $117. Despite this adjustment, GuruFocus indicates that CYTK is significantly undervalued by 65.7%, with a current price of $85.57 against a GF Value of $249.16. The", "url": "https://www.gurufocus.com/news/8947929/cytk-maintained-by-rbc-capital-price-target-lowered-to-117", "source_name": "GuruFocus", "published_at": "2026-07-08T01:40:51", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale", "summary": "Cytokinetics (NASDAQ: CYTK) has filed a Form 144 notice indicating a proposed sale of 24,500 shares of Common Stock through the exercise of stock options on July 7, 2026, with the sale method listed as cash. The filing also disclosed five previous 10b5-1 sales, each for 3,500 sha", "url": "https://www.stocktitan.net/sec-filings/CYTK/144-cytokinetics-inc-sec-filing-5b903de62e87.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:51", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market", "summary": "CYTOKINETICS' EVP of Research & Development, Fady Ibraham Malik, reported an exercise-and-sale transaction, selling 3,500 shares of common stock at $86.62 per share after exercising options to acquire the same number of shares at $7.80 per share. Following these transactions, Mal", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-722b24b08af2.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:51", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Announces Three Late-Breaking Science", "summary": "Cytokinetics (Nasdaq: CYTK) will present three Late-Breaking Science abstracts at the European Society of Cardiology (ESC) Congress in August 2026, including primary results from the pivotal ACACIA-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM). The ", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323061/0/en/Cytokinetics-Announces-Three-Late-Breaking-Science-Abstracts-at-the-European-Society-of-Cardiology-ESC-Congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T13:41:28", "published_display": "07 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating", "summary": "RBC Capital has updated its price target for Cytokinetics, Inc. (CYTK) to $117, down from $119, while reaffirming its Outperform rating on the stock. The adjustment reflects an updated valuation by RBC Capital analysts. Cytokinetics is a biopharmaceutical company focused on devel", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-cytokinetics-price-target-to-117-from-119-maintains-outperform-rating-ce7f5ed8d98efe20", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T12:18:30", "published_display": "07 Jul 2026 12:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics lands three ESC 2026 presentations on heart drug data", "summary": "Cytokinetics (Nasdaq: CYTK) announced that three Late-Breaking Science abstracts have been accepted for presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich. These presentations will include primary Phase 3 ACACIA-HCM results for aficamten in non-obstr", "url": "https://www.stocktitan.net/news/CYTK/cytokinetics-announces-three-late-breaking-science-abstracts-at-the-ya17z2nhdy4a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:15:30", "published_display": "07 Jul 2026 11:15", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK - Cytokinetics Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings and comprehensive financial data for Cytokinetics Inc. (CYTK). It details metrics such as market capitalization, sales, earnings per share (EPS), insider and institutional ownership, profitability ratios, and stock performance over variou", "url": "https://finviz.com/stock?t=CYTK&ty=lf&ta=1&p=w&page=21", "source_name": "Finviz", "published_at": "2026-07-06T05:11:20", "published_display": "06 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com", "summary": "Cytokinetics CEO Robert Blum sold 7,500 shares of company stock worth approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Mr. Blum directly holds 377,830 shares, while the company's stock trades near its 52-week high, having retur", "url": "https://ng.investing.com/news/stock-market-news/cytokinetics-ceo-robert-blum-sells-636900-in-stock-93CH-2585261", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T00:40:39", "published_display": "03 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics CEO Robert Blum sells $636,900 in stock", "summary": "Cytokinetics CEO Robert Blum sold 7,500 shares of the company's common stock for approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following the sale, he directly holds 377,830 shares. The transaction occurs as Cytokinetics shares trade near their 52-week ", "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-ceo-robert-blum-sells-636900-in-stock-93CH-4774389", "source_name": "Investing.com", "published_at": "2026-07-02T21:40:18", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79", "summary": "CYTOKINETICS (NASDAQ: CYTK) EVP and CFO Sung Lee reported exercising 1,112 non-qualified stock options at $48.51 per share and subsequently selling the same number of common shares at $87.79 per share in an open-market transaction. Following these transactions, Lee directly holds", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-3527afafd186.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cytokinetics Inc For: 2 July By Investing.com", "summary": "Investing.com reports on a Form 4 filing for Cytokinetics Inc. on July 2nd. The article reiterates this information and provides general market data, including various stock market indices, commodity prices, bond yields, and trending stocks. It also features popular financial new", "url": "https://ca.investing.com/news/stock-market-news/form-4-cytokinetics-inc-for-2-july-93CH-4719193", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80", "summary": "Andrew Callos, EVP of Cytokinetics (NASDAQ: CYTK), exercised options to acquire 15,000 shares of common stock at $23.26 per share and subsequently sold all 15,000 shares in an open-market transaction at an average price of $85.80 per share on July 1, 2026. Following these transac", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-e4ea3d55d050.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale", "summary": "Cytokinetics President & CEO Robert I. Blum sold 7,500 shares of CYTK common stock at $84.92 per share in an open-market transaction on July 1, 2026. Following the sale, Blum directly holds 377,830 shares, with an additional 2,083 shares each held indirectly by two irrevocable tr", "url": "https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-60c4f7ceaa9c.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:39:41", "published_display": "02 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK)", "summary": "Robert Blum, an insider at Cytokinetics Inc. (CYTK), has filed a Form 144 to report planned sales of company stock, including 44,990 shares from stock option exercise and 7,510 shares from Restricted Stock Units. The filing also details several completed 10b5-1 sales of 7,500 sha", "url": "https://www.stocktitan.net/sec-filings/CYTK/144-cytokinetics-inc-sec-filing-f9b5b5aa47e6.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:28", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Is Up 6.5% After Myqorzo\u2019s Early Commercial Uptake Signals Growing Clinical Interest \u2013 Has The Bull Case Changed?", "summary": "Cytokinetics is seeing a 6.5% stock increase driven by the early commercial success of its heart drug, Myqorzo, which has received regulatory approvals in the US, Europe, and China. The early adoption by physicians and patients is validating the drug's potential, shifting the com", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-up-65-after-myqorzos-early-commercial-u", "source_name": "Simply Wall Street", "published_at": "2026-06-30T22:23:16", "published_display": "30 Jun 2026 22:23", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Inc stock hits 52-week high at $88.00", "summary": "Cytokinetics Inc (CYTK) stock reached a new 52-week high of $88.00, marking a significant 159.39% increase over the past year due to substantial revenue growth and positive analyst sentiment. The company's heart drug, Myqorzo, has seen a successful commercial launch in Germany an", "url": "https://www.investing.com/news/company-news/cytokinetics-inc-stock-hits-52week-high-at-8800-93CH-4768090", "source_name": "Investing.com", "published_at": "2026-06-30T13:40:16", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Prepares for Commercial Rollout Following Regulatory Approvals Across Major Markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxPNWMzTVNSb3UzVTBJLW5XTFF2T2pTMUdmcWNsM25LWXlsN2VkR3d6UU5qR2IzX0ZTTlBITTU1LUJWdHRKOGsyNFBOTjFEdnNGVklPVzZ2cU1qVUppd0hlc3drVzZjZDJNbWRibEtNLUM2N1J4U1BFV0JhQWxuNDlJSkFaRURSVXNOdDhPT0xNUWFOWkgzcjE1dWxPU09ncWI1RHJfRjBVb3NDQnZQazdzRnduVG5GVDNiYjdEM3FpUVBkb0pFM3V0bU1GZU5zMzZrQVdBWDNDeEZNVGFUUzBYczRPcVhTTkdKLTBFN2tkRm9NbEF5WDhpY2xCS2dVMzdJV0dqaFFQSEVVeDVadUd5NTh5LU9WSDg?oc=5", "source_name": "TIKR.com", "published_at": "2026-06-30T12:26:31+00:00", "published_display": "30 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWE82SE0yeTZlbFdFSDhnN2ttZXVEdlN3N3VmSUZuRE5YN3BjNFZiNkxmLTZXY0hqc1FlcDFXQXhfOTVndmh3UTZvWkJPZnZ4NWUwSkJ5TS05UUR0QmVuTWJKTlJQa0ZvcEZvTXZUam8wbGRBVmJBMVhTU1RzSTRMQVZvZHhTU3RBOVlaYWJaUnJhNTRuWGpBa1J0b2JmM2xaTF9ZTHRtOFJGdw?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Stock Surges 19%, With A 8-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNGE3S3BGQ2Zmc2Z5TnVjX3pyWWROWTFxWVlYS0tQUFhvZXBSeUwwTTdQWXhGUzJEZ1IwY1JxUWY0SVJ5SlV1aUYzb2RVQXctRG5wUDlyY3duTWt5RTFtQ2ZPM2MxV3RzZHBfaENRdHN5N0FNRmFIQ2ZxZ1hoaHYwaTJnSFQyOEh6YU1Hdm8zbVRJeDVGeHktLTNOODI4eVg3ajJHc0VMUUs5anpfS0lkdGZNTjFJWGhBUnFhUFNCVzVRWWM?oc=5", "source_name": "Trefis", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Stock 6-Day Winning Spree: Stock Climbs 17%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQaVZ1djhmOVhCOF81NnMxLTFVNTdaSVcxWDBiQmNkM3dBY2UyTmswdm1lMlo3X2kzUmdCMjZTN1NvY2VYSEhSNVJLX3R3Skg2TjFkc051VXVROFU5RmNnX3piVnNBTmlld1NwSExUWWxqRGU4eXRGRmhWdHhsdnBlbUJuLWRtSjYwVVd1Y2doQ2RrLWFPQTFUSjdoMDBYVEVtSjNiNDdWdlFldlEyUjYxVU5lU004dw?oc=5", "source_name": "Trefis", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOc05hRUszeF9MX1NiZDQxcTQ4dnRXeDhtOXZCQnVONDNlUDFBazg3aWZnOXVRYmp3TUVBR1o4dFlyUjhZb1V2ajZwVEtoR0NibDNPMDhuemRrbE1iMVFOVy1QMGFtRjE2XzNBQUxLV2Fna2U1Q0dkU3pWdVhHQVVWYkwtSURLNUZ4TEw0eDFVN3BPTzQ?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics, Inc. (CYTK) Stock Analysis: Exploring a 36.40% Potential Upside in the Biotechnology Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNaU80UGpqb0p0RVIydjN3TGlBNDBrMHhBQ0ZycmdaN0dMcWVRSzVRODhsT3hOemVXQkZaZ2RVTUpRNk5TZS10bFBtcmlBdDctUzJTZGNEallHd01zRzBMRENjODZyZVBVT2Y5NW9rMkVURU5XYzF1UTZPLXhtX3pRM3puSmF4UDVjVUQ0cDMyc2I4TUZGbkstTWw4UEFMaWlHbndQd3BBblJUQ0gwMlpDanZXR1ZHOVBMWlRrcThQZzBmODktcVlaRmMzbEFGX2RTdnFaR283WDdIRDFleEFOc0Fvd0c?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Cytokinetics (CYTK) Valuation After A Strong Multi\u2011Year Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeFQ2SHdnb0VMSW1tSWNQWUdOTzdtakxsYkpQTVotUTZQaVZpUmtTRmNaVnJmWHNKRUZ0LS1TLU02UWhGakkwTzFhb1hWZHI3R0llM1loLVExbnMyamZjemY1MlM0YndGQkhlcjZVNlljRmxwdUd4M0VrSGI0U0Zhcmd0akp0b3pMWXdVRnNST2ZJVDJLaEFDMG5JRldiSlJQRDlwWm1iNA?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: Analysts Are Much More Bullish On Cytokinetics, Incorporated (NASDAQ:CYTK) Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$805M raised as Cytokinetics sells 11.3M shares at $71 each", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQangwS3ZVZjdTSkR5Ylk5X1ZzNmtsc0JuYW5tX19adVhwTk1TOWtFQl9zM3FmTzctUTNDd0FaaUpqVWZGR2ZaZHVTdlVEZmVRTGxlTWJRczhjMGVSWDBySTRvWXh5M3gzOHF2THB1c3NGYkRaTG0zYjNSQWRCMm1CRkkwTW1kOTRzcTBnZnlROHFrb1YzNXhuOEdNRFVhZnNRYmRINDVyeEhEdWl3MGhNOUQ3dVJpZjRUWGxvQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC increases stake in Cytokinetics (NASDAQ: CYTK) to 9.0%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOV0lLanEwTmtPSmNySE9yZllWV3hHUkdNMTBXYTRxOWd5VUkzYTliQUNValJGb2lVMVE1ZTR4X3RMc2ZXY0JrS3EtakxRZHVtRU1GZDlVWEZCV180bXFtOVljTHQwUEN5TkdkenFhX2djbEFvYVJoMy1aaGVJeWJSOWJmbVJDbWxCdUpWZ2NmZ253cTFIaHNyQjk1MWZ1NXJ2OENNMnJSSGRrV3FVbXdvSzhVUEtJcGdYRmJqRkdTaUxPc3dua2hqZnVsNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNb1V4MGVfb0pYTjdFLWM2UzJoSVV3UzhlNmgyY1J3VGk5ZHdodE1ydDkyX3djVmYtd3ZVTkhxVVZleTdmME9PRFdSODRNT2pFVm0tU010T0xvN1RWS1dKN0k2UDdEMjNKRTBvOGxjcVdsVFF2WmVUYWxYcWtmOUpqRDdDaklXVWtVUjE3TWFVWU1pN0dSQWszR3E0bWlxRU94clVkMnNuX3VNSk5xeFRxakU1aFBTRVhaQWhMUkNSTEJLZw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000%", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQelU4T0djbjVOTW5KRHlRSEIzWFgxOUxXbTZZMHo4NWpjbGd6NzZGazlzRkMyRkRNcFhIYXNxeFE0c0VlQUE2SWlkcXYwNG5paWw5cjFvVEZsQVpHQXJKUU56SWY3UEtxOGtZU2ptV0NzaG4yeUZ4U3U1NTZFTlc3VTUtTTJuYjlpdDBOZ1VTeHl5YWZTNnpTVG5NQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOa1ZjbzhlVFJxMk9Lc1RMc2dBeW5qUEx6cDZQVkZuVHpKZ3RkVWcwYlh4bF9xZDg2VE5IRE9uZV9QeXFjYXg0TmhZUmtaYkppM0dqOVFWM0hZdjE0ZGR5dXFsREVaWkFkVjlvY1ZHS1UzM2dwRnUxRlRWa25fSGRjaHRGWXk3cklOY0xKU21KUmJ2dkg3RHRONXJsbkVLMWc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Cytokinetics (CYTK) After Its 62% One-Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVDc2b0hYMV9PV2tZUWdua25zRE03NlRyVHd5MTFPSC0taUx5YklwYm5HTjFRSFdWV1ZEOEs2QUFOVEVicXlxX3lIVHJqMERVSmJTVTVJR29oTFdxQnQ2M1NDQkEzbHB3SjBhZ09NWl9uWklZdDJWZnZMYzMtQU8tYnRwSi1FQW1PRU9VVXpnb0gwamJPSUMtTkNhaXdtcTRpa2E5YWl6bW45T3pwWXhKUUt2ZE1SbTlFSk5PSHRwQTRBUHlVUHJQOU1ZeUJWZHNfSHRqVWVGdE9vdThwNVBj0gHkAUFVX3lxTE5YSE5QN2NGUGFUQ0NIM0lsOURRY3MyaXZ5SnFjTDBZV3FzS1hDUlJoSk9ZWUJVbElfSTRyeWFfbUZWY2NiMGxoN2dUVFB1YllzbnhiYUFDQUtzS1VXLXZhYWo0ZzZNSzZrelZiRnhsMmppbmVSZXFaTE52Tm5pZm5DbHg0LXpjTzN4ZWIwMWk1M1gzYmRHOEVZakhVTXZTS1Y4TWQ3REVZdDB4RDIxYlRVRHNybXo5UEdyc0M4TGFieklFSngtbDZyd2hvcGh1Ui1TUUdfcURrN3ZLMF9lbWRoWng3VQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 64, "sentiment_summary": {"positive": 22, "negative": 5, "neutral": 37, "score": 55, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 84.87, "latest_week": "2026-07-10", "one_week_move": -1.9, "four_week_move": 21.0, "twelve_week_move": 27.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.225271, "market_dynamics_buy_signal": false, "relative_strength": 19.594126, "fair_value_gap": 58.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.7808, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.9% over one week, +21.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 11}, {"label": "simplywall.st", "count": 7}, {"label": "Simply Wall Street", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Investing.com Canada", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "DirectorsTalk Interviews", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.9% over one week, +21.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy"}], "updated_at": "2026-07-16T08:05:30.713270+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}